Happe, Svenja

[["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Peglau, Ines"],["dc.contributor.author","Mayer, G."],["dc.contributor.author","Giani, Guido"],["dc.contributor.author","Geraedts, Max"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Dodel, R."],["dc.date.accessioned","2018-11-07T11:07:35Z"],["dc.date.available","2018-11-07T11:07:35Z"],["dc.date.issued","2007"],["dc.format.extent","A281"],["dc.identifier.isi","000246224900820"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52601"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Academy Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","21st Annual Meeting of the Association-Professional-Sleep-Societies"],["dc.relation.eventlocation","Minneapolis, MN"],["dc.relation.issn","0161-8105"],["dc.title","Direct and indirect costs of restless legs syndrome (RLS)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Hogl, Birgit"],["dc.contributor.author","Gschliesser, V."],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Hadjigeorgiu, G."],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","de Weerd, Al W."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Kohnen, Ralf"],["dc.date.accessioned","2018-11-07T08:48:03Z"],["dc.date.available","2018-11-07T08:48:03Z"],["dc.date.issued","2005"],["dc.format.extent","A272"],["dc.identifier.isi","000228906101316"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21113"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Academy Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","19th Annual Meeting of the Associated-Professional-Sleep-Societies"],["dc.relation.eventlocation","Denver, CO"],["dc.relation.issn","0161-8105"],["dc.title","Augmentation during long-term treatment with L-DOPA in restless legs syndrome: Results of a multicentric study in Europe"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","230"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","237"],["dc.bibliographiccitation.volume","257"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","de Weerd, A. L."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Gschliesser, Viola"],["dc.contributor.author","Egatz, Renata"],["dc.contributor.author","Frauscher, Birgit"],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Hening, Wayne A."],["dc.contributor.author","Allen, Richard P."],["dc.date.accessioned","2018-11-07T08:46:22Z"],["dc.date.available","2018-11-07T08:46:22Z"],["dc.date.issued","2010"],["dc.description.abstract","The European Restless Legs Syndrome (RLS) Study Group performed the first multi-center, long-term study systematically evaluating RLS augmentation under levodopa treatment. This prospective, open-label 6-month study was conducted in six European countries and included 65 patients (85% treatment naive) with idiopathic RLS. Levodopa was flexibly up-titrated to a maximum dose of 600 mg/day. Presence of augmentation was diagnosed independently by two international experts using established criteria. In addition to the augmentation severity rating scale (ASRS), changes in RLS severity (International RLS severity rating scale (IRLS), clinical global impression (CGI)) were analyzed. Sixty patients provided evaluable data, 35 completed the trial and 25 dropped out. Augmentation occurred in 60% (36/60) of patients, causing 11.7% (7/60) to drop out. Median time to occurrence of augmentation was 71 days. The mean maximum dose of levodopa was 311 mg/day (SD: 105). Patients with augmentation compared to those without were significantly more likely to be on higher doses of levodopa (a parts per thousand yen300 mg, 83 vs. 54%, P = 0.03) and to show less improvement of symptom severity (IRLS, P = 0.039). Augmentation was common with levodopa, but could be tolerated by most patients during this 6-month trial. Patients should be followed over longer periods to determine if dropout rates increase with time."],["dc.description.sponsorship","Pharmacia (now Pfizer) USA"],["dc.identifier.doi","10.1007/s00415-009-5299-8"],["dc.identifier.isi","000274251700011"],["dc.identifier.pmid","19756826"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6747"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20677"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","0340-5354"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S495"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","S504"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Allen, Richard P."],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","Klein, Christine"],["dc.contributor.author","Nass, Alexander"],["dc.contributor.author","Montagna, Pasquale"],["dc.contributor.author","Oertel, Wolfgang Hermann"],["dc.contributor.author","O'Keeffe, Shaun"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Poewe, Werner"],["dc.contributor.author","Provini, Federica"],["dc.contributor.author","Pramstaller, Peter P."],["dc.contributor.author","Sieminski, Mariusz"],["dc.contributor.author","Sonka, Karel"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","de Weerd, A. L."],["dc.contributor.author","Wetter, Thomas C."],["dc.contributor.author","Winkelmann, Juliane"],["dc.contributor.author","Zucconi, Marco"],["dc.date.accessioned","2018-11-07T11:07:07Z"],["dc.date.available","2018-11-07T11:07:07Z"],["dc.date.issued","2007"],["dc.description.abstract","The European Restless Leas Syndrome (RLS) Study Group (EURLSSG) is an association of European RLS experts who are actively involved in RLS research. A major aim of the Study Group is the development and continuous improvement of standards for diagnosis and treatment of RLS. Several members developed study designs and evaluation methods in investigator-initiated trials early in the 1990s, and all members have since contributed to many pivotal and nonpivotal drug trials for the treatment of RLS. The recommendations on clinical investigations of pharmacological treatment of RLS patients summarize the group's expertise and knowledge acquired through clinical trials. The recommendations primarily address how to plan and conduct confirmatory, randomized clinical studies in patients with idiopathic RLS. Advice is presented for the diagnosis of RLS and clinical and polysomnographic inclusion and exclusion criteria. Primary and secondary endpoints for an evaluation of efficacy are based on a critical description of validated methods for both short- and long-term trials, also in special populations (children, pregnant women, elderly patients). The recommendations include the assessment of augmentation. Finally, general issues including the evaluation of safety and tolerability, as well as specific neurological and cardiovascular risks and sleep attacks/daytime somnolence, are discussed. The aim of these recommendations is to support research groups or pharmaceutical companies in the design of optimized study protocols. (C) 2007 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.21538"],["dc.identifier.isi","000251605200015"],["dc.identifier.pmid","17530666"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52479"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Scientific Symposium and Augmentation Workshop on Restless Leg Syndrome"],["dc.relation.eventlocation","Max Planck Inst Phys Complex Syst, Munich, GERMANY"],["dc.relation.issn","1531-8257"],["dc.relation.issn","0885-3185"],["dc.title","Clinical trials in restless legs syndrome - Recommendations of the European RLS study group (EURLSSG)"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","295"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Sleep Medicine"],["dc.bibliographiccitation.lastpage","305"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Reese, Jens Peter"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Peglau, Ines"],["dc.contributor.author","Mayer, Geert"],["dc.contributor.author","Klotsche, Jens"],["dc.contributor.author","Giani, Guido"],["dc.contributor.author","Geraedts, Max"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Dodel, Richard"],["dc.date.accessioned","2018-11-07T08:32:32Z"],["dc.date.available","2018-11-07T08:32:32Z"],["dc.date.issued","2009"],["dc.description.abstract","Background: Restless Legs Syndrome (RLS) has a substantial impact on normal daily activities. Because of the high prevalence it is necessary to evaluate the impact on the health-related quality of life (HRQoL). Objective: To assess health-related quality of life in patients with RLS. Methods: A total of 519 patients (327 female patients; mean age: 64.2 y) were recruited in five different German centers according to the diagnostic criteria of the International RLS Study Group. Patients were either interviewed or completed a mailed questionnaire. The questionnaire consisted of an evaluation of the sociodemographic, clinical and health-related status. HRQoL was evaluated with the EuroQoL (EQ-5D). In addition, the IRLS scale, the MOS Sleep Scale, the Epworth Sleepiness Scale, and the BDI were applied as clinical rating scales. Results: HRQoL is substantially affected by RLS. The mean EQ-5D-VAS was 55.6 and considerably lower compared to the general population. It was found to be as low as in other chronic neurological disorders such as Parkinson's disease and stroke. From different, factors investigated by uni- and multivariate analyses, severity of RLS and depressive symptoms had the most significant impact on HRQoL. Additionally, sleep deficits, the duration of the disease and net household income were identified as predictors for different EQ-5D outcome scores. Conclusions: RLS considerably affects HRQoL. Further comparative studies are necessary to evaluate the effect of disease symptoms on HRQoL and their change due to medication. (C) 2008 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.sleep.2008.01.002"],["dc.identifier.isi","000266225000005"],["dc.identifier.pmid","18359664"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17362"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1878-5506"],["dc.relation.issn","1389-9457"],["dc.title","Assessing health-related quality of life in patients with restless legs syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","207"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","212"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Kemlink, David"],["dc.contributor.author","Polo, Olli"],["dc.contributor.author","Montagna, Pasquale"],["dc.contributor.author","Provini, Federica"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Oertel, Wolfgang"],["dc.contributor.author","de Weerd, A. L."],["dc.contributor.author","Nevsimalova, Sona"],["dc.contributor.author","Sonka, Karel"],["dc.contributor.author","Hogl, Birgit"],["dc.contributor.author","Frauscher, Birgit"],["dc.contributor.author","Poewe, Werner"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Pramstaller, Peter P."],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Zucconi, Marco"],["dc.contributor.author","Konofal, Eric"],["dc.contributor.author","Arnulf, Isabelle"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Klein, Christine"],["dc.contributor.author","Hiller, Anja"],["dc.contributor.author","Lichtner, Peter"],["dc.contributor.author","Meitinger, Thomas"],["dc.contributor.author","Mueller-Myshok, Betram"],["dc.contributor.author","Winkelmann, Juliane"],["dc.date.accessioned","2018-11-07T11:05:44Z"],["dc.date.available","2018-11-07T11:05:44Z"],["dc.date.issued","2007"],["dc.description.abstract","Three loci for the restless legs syndrome (RLS) on chromosomes 12q, 14q, and 9p (RLS 1, RLS2, and RLS3) have been mapped, but no gene has been identified as yet. RLS1 has been confirmed in families from three different populations. We conducted a family-based association study of 159 European RLS trios. The subjects were genotyped using microsatellite markers evenly covering the candidate regions on chromosomes 14q and 9p with an average intermarker distance of 1.1 cM. Transmission disequilibrium tests were used to analyze the data, and empirical P values were estimated by permutation testing. On chromosome 14q, a significant association (empirical P = 0.0033) was found with a haplotype formed by markers D14S1014 and D14S1017 when analyzing all families. On chromosome 9p, no significant association in the sample of all families and only marginally significant associations were detected, with a haplotype involving markers D9S1846-D9S171 in a subset of South European trios and with a haplotype at D9S156-D9S157 in a subset of Central European trios (P = 0.0086 and 0.0077, respectively). These results represent the first confirmation of these loci in a mixed European population. Variable results observed in families of different ethnic groups further corroborate the genetic complexity of RLS. (C) 2006 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.21254"],["dc.identifier.isi","000243944800010"],["dc.identifier.pmid","17133505"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52130"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1531-8257"],["dc.relation.issn","0885-3185"],["dc.title","Family-based association study of the loci 2 and 3 in a European restless legs syndrome population"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","455"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Sleep Medicine"],["dc.bibliographiccitation.lastpage","463"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","de Weerd, Al W."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Gschliesser, Viola"],["dc.contributor.author","Egatz, Renata"],["dc.contributor.author","Cabrero, Belen"],["dc.contributor.author","Frauscher, Birgit"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Hening, Wayne A."],["dc.contributor.author","Allen, Richard P."],["dc.date.accessioned","2018-11-07T11:00:28Z"],["dc.date.available","2018-11-07T11:00:28Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: Augmentation is the main complication during long-term dopaminergic treatment of restless legs syndrome (RLS) and reflects an overall increase in RLS severity. Its severity varies considerably from a minor problem to a devastating exacerbation of disease. Despite its clinical relevance, systematic evaluations have rarely been undertaken and there has been no development of methods to assess the severity of augmentation. To fill this gap, the European RLS Study Group (EURLSSG) has developed the Augmentation Severity Rating Scale (ASRS), using three items that assess the degree of change in three specific dimensions of augmentation. The changes in each dimension are summed to give an ASRS total score. Methods: The ASRS was developed to cover the basic dimensions defining RLS augmentation. The items were developed by an interactive process involving professional and patient input. The ASRS that was evaluated included four major items and two alternative forms of one item. The validation was conducted using 63 (85%) mostly untreated RLS patients from six centers, who were treated for six months with levodopa (L-Dopa) (up to 500 mg/day, as clinically needed). Two consecutive assessments before and at baseline measured test-retest reliability. Consecutive ASRS ratings by two independent raters on a subsample of patients evaluated inter-rater reliability. Comparison with clinical severity ratings of two independent experts provided external validation of the ASRS. Comparison of patients with and without augmentation with regard to the items and the total score of the ASRS added discriminant validity. Results: Sixty patients (63% females, mean age: 53 years, baseline International RLS Severity Rating (IRLS) score 24.7 +/- 5.2) were treated with a median daily dose of 300 mg L-Dopa (range: 50-500 mg). Thirty-six patients (60%) experienced augmentation. Item analyses indicated that one item could be removed as it did not contribute significantly to the test score and only one form of the duplicated item needed to be used. The final ASRS then included three items. Test-retest reliability for the total score was rho = 0.72, and inter-rater reliability was rcc = 0.94. Cronbach's alpha was 0.62. Validity as assessed by the correlation between the worst ASRS total score during the trial and the expert rating was p = 0.72. ASRS total score differed between patients without versus with augmentation (mean: 7.4 (standard deviation (SD) = 4.0) vs. 2.0 (2.7) (P < 0.0001). Conclusions: The ASRS is a reliable and valid scale to measure the severity of augmentation. Due to the need to systematically quantify augmentation for both long-term efficacy and tolerability, the ASRS may become a useful tool to monitor augmentation in future clinical trials. (C) 2007 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.sleep.2007.03.023"],["dc.identifier.isi","000248955800001"],["dc.identifier.pmid","17543579"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50923"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1878-5506"],["dc.relation.issn","1389-9457"],["dc.title","Validation of the Augmentation Severity Rating Scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Gschliessl, V."],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Hadjigeorgiu, G."],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","de Weerd, Al W."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Kohnen, Ralf"],["dc.date.accessioned","2018-11-07T10:42:30Z"],["dc.date.available","2018-11-07T10:42:30Z"],["dc.date.issued","2006"],["dc.format.extent","A289"],["dc.identifier.isi","000237916701226"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46812"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Acad Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","20th Annual Meeting of the Associated-Professional-Sleep-Societies"],["dc.relation.eventlocation","Salt Lake City, UT"],["dc.relation.issn","0161-8105"],["dc.title","Augmentation during long-term treatment with L-DOPA: Results of a multicentre study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","381"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","PharmacoEconomics"],["dc.bibliographiccitation.lastpage","393"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Dodel, Richard"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Peglau, Ines"],["dc.contributor.author","Mayer, Geert"],["dc.contributor.author","Wasem, Juergen"],["dc.contributor.author","Reese, Jens-Peter"],["dc.contributor.author","Giani, Guido"],["dc.contributor.author","Geraedts, Max"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Oertell, Wolfgang H."],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.date.accessioned","2018-11-07T08:48:23Z"],["dc.date.available","2018-11-07T08:48:23Z"],["dc.date.issued","2010"],["dc.description.abstract","Background: The primary characteristics of restless legs syndrome (RLS), including severe sleep disorders, restlessness in the evening and discomfort while at rest, have substantial impact on normal daily activities. Because of the high prevalence of RLS in the general population, it is necessary to evaluate the economic impact of RLS. Objective: To determine the health economic burden of patients with RLS in Germany. Methods: A total of 519 RLS patients (mean age: 65.2 +/- 11.1 years) in different stages of disease were recruited in five health centres (university hospitals, district hospitals and office-based neurologists) by applying the diagnostic criteria of the International Restless Legs Syndrome Study Group. A questionnaire was administered that assessed healthcare resource consumption as well as socioeconomic, demographic, clinical and health status. In addition, the International RLS severity scale (IRLS), Epworth Sleepiness Scale (ESS), EQ-5D and Beck Depression Inventory (BDI) were addressed in the assessment. Direct and indirect costs ((sic), year 2006 values) were derived from various German economic resources and calculated from the perspective of the healthcare and transfer payment providers. Results: We calculated average total costs over the 3-month observation period. It was determined that average total costs were (sic)2090 for this period. The average direct medical and non-medical costs from the perspective of the health insurance provider were determined to be (sic)780, with (sic)300 attributed to drug costs and (sic)354 to hospitalization costs. Average total indirect costs amounted to (sic)1308 and were calculated based on productivity loss, using the human capital approach. As cost-driving factors we identified disease severity according to the IRLS (p < 0.01) and ESS (p < 0.04). Health-related quality of life was determined to be substantially affected by RLS; the mean EQ-5D visual analogue scale (VAS) was 55.6, considerably lower than that of the age-matched general population. Conclusion: RLS places a notable financial burden on society as well as on patients and their families. More detailed studies are needed to evaluate the health economic impact of this disorder."],["dc.description.sponsorship","German Ministry of Education and Research [01GI9901/1]"],["dc.identifier.isi","000277769200004"],["dc.identifier.pmid","20297866"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21193"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Adis Int Ltd"],["dc.relation.issn","1170-7690"],["dc.title","Health Economic Burden of Patients with Restless Legs Syndrome in a German Ambulatory Setting"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S449"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","S458"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Winkelmann, Juliane"],["dc.contributor.author","Polo, Oli"],["dc.contributor.author","Provini, Federica"],["dc.contributor.author","Nevsimalova, Sonja"],["dc.contributor.author","Kemlink, David"],["dc.contributor.author","Sonka, Karel"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Poewe, Werner"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Oertel, Wolfgang"],["dc.contributor.author","de Weerd, A. L."],["dc.contributor.author","Strambi, Luigi Ferini"],["dc.contributor.author","Zucconi, Marco"],["dc.contributor.author","Pramstaller, Peter P."],["dc.contributor.author","Arnulf, Isabelle"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Klein, Christine"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Rye, David"],["dc.contributor.author","Montagna, Pasquale"],["dc.date.accessioned","2018-11-07T11:07:08Z"],["dc.date.available","2018-11-07T11:07:08Z"],["dc.date.issued","2007"],["dc.description.abstract","Several studies demonstrated that 60% of restless legs syndrome (RLS) patients have a positive family history and it has been suggested that RLS is a highly hereditary trait. To date, several loci have been mapped but no gene has been identified yet. Phenocopies and possible nonpenetrants made it difficult to detect a common segregating haplotype within the families. Defining the exact candidate region is hampered by possible intrafamilial, allelic, and nonallelic heterogeneity. One important prerequisite for future successful genetic studies in RLS is the availability of large and thoroughly phenotyped patients and family samples for linkage as well as association studies. (C) 2007 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.21587"],["dc.identifier.isi","000251605200010"],["dc.identifier.pmid","17557342"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52481"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Scientific Symposium and Augmentation Workshop on Restless Leg Syndrome"],["dc.relation.eventlocation","Max Planck Inst Phys Complex Syst, Munich, GERMANY"],["dc.relation.issn","0885-3185"],["dc.title","Genetics of restless legs syndrome (RLS): State-of-the-art and future directions"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]